Neoadjuvant Chemotherapy in Stadium IB3, IIA2 and IIB Cervical Cancer a Narrative Review
I Gde Sastra Winata1*
, I Nyoman Gede Budiana1, I Made Jawi2 and Ketut Suwiyoga11Department of Obstetrics and Gynaecology of Sanglah General Hospital/Faculty of Medicine, Udayana University, Denpasar, Indonesia.
2Department of Pharmacology of Faculty of Medicine of Udayana University, Denpasar, Indonesia.
Corresponding Author E-mail: sastra@unud.ac.id
Abstract: This study aimed to describe Paclitaxel-Carboplatin chemotherapy as neoadjuvant chemotherapy in stage IB3, IIA2 and IIB cervical cancer. The review was conducted by collecting journals from previous studies discussing neoadjuvant chemotherapy in cervical cancer stages IB3, IIA2, and IIB and in this case specifically discussing Paclitaxel-Carboplatin chemotherapy. Neoadjuvant chemotherapy refers to systemic therapy intended to reduce the size of the tumour before the definitive operation. Several studies have shown that neoadjuvant chemotherapy has greater advantages than surgery alone for early stage cancers (IB3, IIA2, and IIB). Paclitaxel and Carboplatin are known chemotherapeutic agents that can be used as neoadjuvant chemotherapy. Neoadjuvant Chemotherapy regimen Paclitaxel Carboplatin is one of the options in performing therapy for early stage cervical cancer which can be very helpful in healing and cancer-free patient condition. Neoadjuvant chemotherapy followed by radical surgery has significant benefits that have been described in several previous studies. Neoadjuvant Chemotherapy regimen Paclitaxel Carboplatin may be used as therapy regimen for early stage cervical cancer with all advantage compared to only surgery. Thus, this type of regimen can be used to decrease mortality and morbidity in patient with stadium IB3, IIA2 and IIB cervical cancer.
Keywords: Carboplatin; Neoadjuvant Chemotherapy; Paclitaxel; Stadium IB3, IIA2 and IIB cervical cancer Back to TOC